MS4A1 and acute lymphoblastic leukemia: In this retrospective study, we focused not only on the CD20 proportion but also on the CD20 intensity and found that their different prognostic values, that is, low CD20 MFI or high CD20 proportion, can be used as an independent indicator of inferior prognosis for B‐ALL patients, and these were applied to ALL patients with different clinical factors.